Cadila Healthcare Ltd.
Snapshot View

585.95 +14.05 ▲2.5%

30 July 2021, 04:00:00 P.M.
Volume: 221,450

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.zyduscadila.com
Financial Indicators
Market Cap 59,986.20 Cr.
Earnings per share (EPS) 20.84 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 28.12 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 126.91 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.62 Calculated using Price: 585.95
Dividend Yield 0.60 Period Ending 2021-03
No. of Shares Subscribed 102.37 Cr. 1,023,742,600 Shares
FaceValue 1
Company Profile

Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Business verticals / products

  • Human Health Formulations
  • Consumer Wellness
  • Animal Healthcare

Awards

2008-09:

  • The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

  • Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
  • Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

  • Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

  • Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

  • The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

  • Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

  • The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
  • The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

  • It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

  • Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

  • The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
  • API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

  • Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20:

  • Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.46%
1 Week
-4.73%
1 Month
-9.16%
3 Month
+2.58%
6 Month
+29.78%
1 Year
+60.31%
2 Year
+165.98%
5 Year
+60.07%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 24.95 26.20 30.85 38.62 23.43 22.26 19.36 11.32 18.30
Return on Capital Employed (%) 18.21 17.67 23.21 28.60 16.50 18.41 15.89 10.02 13.65
Return on Assets (%) 10.00 10.89 13.93 20.14 12.18 11.11 9.34 5.18 9.37

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 2,945 3,439 4,252 5,699 6,960 8,745 10,386 10,376 12,992
Non Curr. Liab. 1,640 1,589 1,342 736 1,903 2,122 3,491 2,854 19
Curr. Liab. 2,670 2,814 3,285 3,461 5,306 6,083 7,343 8,269 7,861
Minority Int. 119 144 169 136 156 191 1,293 1,335 1,937
Equity & Liab. 7,374 7,987 9,047 10,032 14,325 17,141 22,513 22,834 22,810
Non Curr. Assets 4,183 4,549 4,820 5,752 8,303 8,911 14,015 14,118 14,094
Curr. Assets 3,192 3,438 4,227 4,280 6,022 8,230 8,498 8,715 8,716
Misc. Exp. not W/O
Total Assets 7,374 7,987 9,047 10,032 14,325 17,141 22,513 22,834 22,810

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 6,358 7,224 8,651 9,427 9,377 11,955 13,166 14,253 15,102
Other Income 38 86 57 117 147 133 209 117 45
Total Income 6,396 7,310 8,709 9,543 9,524 12,088 13,374 14,370 15,147
Total Expenditure -5,234 -6,031 -6,897 -7,097 -7,475 -9,126 -10,187 -11,473 -11,764
PBIDT 1,162 1,279 1,811 2,446 2,049 2,962 3,187 2,897 3,384
Interest -169 -118 -68 -53 -63 -111 -196 -342 -169
Depreciation -185 -201 -287 -292 -373 -539 -599 -697 -725
Taxation -119 -106 -259 -177 -129 -564 -530 -320 -147
Exceptional Items -17 -10 -3 0 -10 -364 -205
PAT 690 836 1,186 1,921 1,483 1,748 1,852 1,176 2,138

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 603 903 994 1,894 1,312 919 1,282 2,932 3,293
Cash Fr. Inv. -682 -438 -465 -864 -2,872 -974 -4,239 -1,012 -723
Cash Fr. Finan. 286 -529 -351 -935 2,316 52 1,885 -1,528 -2,549
Net Change 207 -64 178 95 756 -3 -1,072 391 22
Cash & Cash Eqvt 677 613 790 837 1,593 1,590 779 1,178 1,087

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 74.79 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88
Public 25.21 25.12 25.12 25.12 25.12 25.12 25.12 25.12 25.12
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated titled Zydus Cadila receives final approval from USFDA for Fulvestrant Injection
Wed, 21 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)
Wed, 21 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets

Technical Scans View Details

Fri, 30 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Piramal Enterprises Ltd. 52,749.34 2,323.00 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 39.59 2,323.00 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1.54 2,323.00 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,323.00 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,323.00 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,323.00 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,323.00 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,323.00 +0.2%